This week, we sat down with Mindful Choices Chief Science Officer, Shanta Whitaker, PhD, MPH, to discuss why research matters, emerging areas of innovation, and where future investments could have the greatest impact for the ADHD community.
Research is essential to advancing care across many mental health conditions. For ADHD specifically, why is continued research so important for patients, families, clinicians, and policymakers?
Research is how we continue improving care for people with ADHD. While we’ve learned a great deal over the past several decades, there is still much we don’t know about why ADHD affects people differently, which treatments work best for whom, and how needs change across the lifespan.
For clinicians, research provides the evidence needed to make informed treatment decisions. For patients and families, it helps separate facts from misinformation and supports shared decision-making. For policymakers, it provides the data needed to improve access to care and develop policies grounded in evidence rather than assumptions.
Most importantly, continued research moves us closer to more personalized, effective care that helps people with ADHD thrive.
As our understanding of ADHD continues to evolve, what emerging areas of research do you see as having the greatest opportunity to improve patient care?
Several areas are especially promising.
One is diagnostic innovation. Researchers are exploring digital tools, objective measures, and other technologies that could complement comprehensive clinical evaluations and help improve the accuracy and timeliness of diagnosis.
We are also seeing continued innovation in medications, therapies, and care-delivery models. As more options become available, research will be essential to understanding which approaches are most effective for different patients, at different ages, and under different circumstances.
Another promising area is the study of behavioral and lifestyle interventions, including sleep, exercise, nutrition, mindfulness, therapy, and coaching. Many people find these strategies helpful, but we need stronger evidence about who benefits, under what conditions, and how these approaches can be integrated with medication and other forms of treatment.
Across each of these areas, the goal should be to give patients and clinicians better information so they can make informed decisions together and develop care plans that reflect each person’s needs.
Looking ahead, where should future federal research investments be focused to have the greatest impact on the ADHD community?
Future research should focus on the questions that matter most to people living with ADHD and the clinicians and families who support them.
That includes improving the accuracy and accessibility of diagnosis, studying long-term outcomes across the lifespan, evaluating new and emerging treatments, and strengthening the evidence base for behavioral and lifestyle interventions. We also need more research on how ADHD interacts with co-occurring conditions and how care can be better coordinated across health, education, and community settings.
Importantly, research must reflect the full spectrum of the ADHD community. That means ensuring greater representation of women and girls, adults and older adults, underserved populations, and people with co-occurring physical and mental health conditions.
Federal investment is especially important because it supports independent, large-scale, and long-term research that may not otherwise occur. Those investments can help translate scientific discoveries into better clinical care, more informed public policy, and improved outcomes for patients and families.